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P5-Year Clinical Outcomes of the ARTS II
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of Patients With Multivessel De Novo
Coronary Artery Lesions
Patrick W. Serruys, MD, PHD,* Yoshinobu Onuma, MD,* Scot Garg, MBCHB,* Pascal Vranckx, MD,†
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Madrid, Spain; and Bad Segeberg and Bad Nauheim, Germany
Objectives The purpose of this study is to compare the 5-year clinical outcomes, safety, and efficacy of sirolimus-eluting
stents (SES) in the ARTS II (Arterial Revascularization Therapies Study II) with the outcomes of coronary artery
bypass graft (CABG) and bare-metal stenting (BMS) from the ARTS I.
Background The long-term outcomes after SES implantation in patients with multivessel disease remains to be established.
Methods The ARTS I was a randomized trial of 1,205 patients with multivessel disease comparing CABG and BMS. The ARTS II study
was a nonrandomized trial with the Cypher sirolimus-eluting stent (Cordis, a Johnson & Johnson Company, Warren, New
Jersey), applying the same inclusion and exclusion criteria, end points, and protocol definitions. The ARTS II trial enrolled
607 patients, with an attempt to enroll at least one-third of patients with 3-vessel disease.
Results At 5-year, the death/stroke/myocardial infarction event-free survival rate was 87.1% in ARTS II SES, versus
86.0% (p  0.1) and 81.9% (p  0.007) in ARTS I CABG and BMS cohorts, respectively. The 5-year major ad-
verse cardiac and cerebrovascular event (MACCE) rate in ARTS II (27.5%) was significantly higher than ARTS I
CABG (21.1%, p  0.02), and lower than in ARTS I BMS (41.5%, p  0.001). The cumulative incidence of defi-
nite stent thrombosis was 3.8%. Thirty-two percent (56 of 176) of major adverse cardiac events (MACE) at 5
years were related to possible, probable, or definite stent thrombosis.
Conclusions At 5 years, SES had a safety record comparable to CABG and superior to BMS, and a MACCE rate that was
higher than in patients treated with CABG, and lower than in those treated with BMS. Approximately one-third of
the events seen with SES could be prevented through the elimination of early, late, and very late stent
thrombosis. (J Am Coll Cardiol 2010;55:1093–101) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.049n
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009, accepted November 30, 2009.ary Revascularization), SIRIUS (Randomized Study with
he Sirolimus-Coated Bx Velocity Balloon-Expandable
tent in the Treatment of Patients with de Novo Native
oronary Artery Lesions), and TAXUS VI studies have all
emonstrated the efficacy and safety of drug-eluting stents
DES) compared with bare-metal stent (BMS) at 5-year
ollow-up (1–3). These studies, however, enrolled patients
ith simple de novo lesions, and although important, their
esults are not applicable to the 60% to 70% of today’s
ercutaneous coronary intervention (PCI) patients who
eceive DES for “off-label” indications (4). Compared with
on-label” use, the use of DES for off-label indications is
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5-Year Outcomes of the ARTS II Trial March 16, 2010:1093–101associated with poorer outcomes
and a higher risk of stent throm-
bosis (ST); conversely, for off-
label lesions, DES are associated
with superior outcomes when
compared with BMS (4 – 8).
These data are limited to only
short- and medium-term follow-
up, and the outcomes at 5 years
in this complex patient group
remain to be fully established.
The ARTS II (Arterial Revascu-
larization Therapies Study II)
population clearly represents off-
label use of sirolimus-eluting
stents (SES), with a mean of 3.7
stents implanted per patient, and
a mean total stent length of 72.5
mm per patient. Therefore, al-
though a nonrandomized trial,
ARTS II can address important
issues regarding the safety of
DES implantation in patients
with complex multivessel disease.
The present analysis is the final report on the 5-year
afety and effectiveness of the SES in patients with
ultivessel disease: it compares the outcomes of ARTS II
ith the outcomes of the 2 historical arms of ARTS I,
nd assesses the impact on long-term outcome of ST,
hich has been readjudicated according to the new
cademic Research Consortium (ARC) definitions (9).
ethods
tudy design. ARTS II was a multicenter, nonrandom-
zed, open-label trial designed to compare the safety and
fficacy of the SES in patients with de novo multivessel
oronary artery disease, with the surgical group of ARTS I
cting as a historical control (10–16). In order to obtain a
opulation comparable to ARTS I, patients were stratified
y clinical site in order to ensure the inclusion of at least
ne-third of patients with 3-vessel disease. The details of
atient selection and end point definitions are described
lsewhere (16–21). In the current analysis, the ARTS II
opulation, the PCI arm, and CABG arm from the ARTS
trials are labeled as SES, BMS, and coronary artery bypass
raft (CABG) groups, respectively.
tudy objectives. The primary objective of ARTS II was to
ompare the safety and effectiveness of coronary stent
mplantation using the SES with the surgical arm of ARTS I.
nd points are measured in terms of major adverse cardiac
nd cerebrovascular events (MACCE) comprising all-cause
eath, any cerebrovascular accident (CVA), nonfatal myo-
ardial infarction (MI), or any repeat revascularization,
hich is equivalent to the patient-oriented clinical end
Abbreviations
and Acronyms
ARC  Academic Research
Consortium
BMS  bare-metal stent(s)
CABG  coronary artery
bypass graft
CVA  cerebrovascular
accident
DES  drug-eluting stent(s)
MACCE  major adverse
cardiac and
cerebrovascular event(s)
MACE  major adverse
cardiac event(s)
MI  myocardial infarction
OR  odds ratio
PCI  percutaneous
coronary intervention
SES  sirolimus-eluting
stent(s)
ST  stent thrombosisoints of ARC definition (9). wThe secondary objectives of this study were to compare
he ARTS II patients with both arms of ARTS I with
espect to: MACCE at 30 days and 1, 3, and 5 years; the
omposite end point of death, CVA, and MI; the itemized
utcomes of death, CVA, MI, and repeat revascularization;
esource utilization at 30 days and 1 year; cost effectiveness
t 1 year; and quality of life at 6 months and 1, 3, and 5
ears. Finally, the study aimed at describing the prognostic
alue of the SYNTAX score (22,23) on the MACCE rates
n the ARTS II population.
The tertiary objectives of the current study were to report
he rate of ST and major cardiac adverse events (MACE;
efined as a composite of all-cause death, nonfatal MI, or
epeat revascularization) with post hoc readjudication of
vents according to the ARC definition, which was first
escribed during the follow-up of this trial (9).
nd point measurement. In ARTS II, the interventional
rocedure was performed within 48 h of inclusion,
hereas in ARTS I, patients were randomized after
nformed consent had been obtained, after which, pa-
ients were placed on a waiting list; there were 3 deaths
n the ARTS I CABG arm while patients were awaiting
evascularization. To compensate for the temporal differ-
nce in allocation between groups, events for the present
eport were counted from the time of the procedure for
ll 3 arms and not from the time of allocation as
reviously published.
In ARTS I and II, only data on subacute thrombotic
cclusion (30 days) were collected in the case record
orm. In ARTS II, ST was readjudicated according to the
RC definitions. In this process, all coronary angiograms,
oth procedure-related (n 104) and nonprocedure-related
n 165), were reviewed by an independent core laboratory
nd adjudicated by an independent critical event committee.
hus far, no attempt has been made to assess data on ST in
RTS I in a similar fashion.
In addition, a detailed coronary risk score that has been
reviously published and tested in a subgroup of ARTS II
atients with 3-vessel disease (the SYNTAX score) was
sed to characterise the complexity of the coronary anatomy
19). In brief, each coronary lesion producing 50% lumi-
al obstruction, in vessels 1.5 mm, was separately scored
nd added to provide the overall SYNTAX score. The
YNTAX score was calculated using dedicated software
hat integrates the number of lesions with their specific
eighting factors based on the amount of myocardium
istal to the lesion according to the score of Leaman et al.
24), and the morphologic features of each single lesion, as
reviously reported (23). This SYNTAX score is now
vailable for the entire ARTS II population and its impli-
ations in terms of prognosis at 5 years are reported in the
urrent paper.
tatistical analysis. Binary variables are reported as per-
entages, and the difference between groups was presented
ith 95% confidence intervals. Time-to-event variables are
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March 16, 2010:1093–101 5-Year Outcomes of the ARTS II Trialresented as Kaplan-Meier curves, and incidences were
ompared using the log-rank test.
A separate multivariate regression analysis was per-
ormed to determine independent predictors of MACE
nd ST (according to ARC definition) within the ARTS
I population only. The following variables were tested
n a per patient basis by univariate analysis to determine
uitability for inclusion in the multivariate model: sex,
revious history of MI, current smoking habit, left
entricular ejection fraction, presence of diabetes, hyper-
ension, 3-vessel disease, family history of MI or sudden
eath at age 55 years, presentation with unstable
ngina, use of glycoprotein IIb/IIIa inhibitors, logistic
uroSCORE, and SYNTAX score. Finally, a logistic
egression model was built using the significant univariate
redictors (p  0.1).
esults
aseline and procedural characteristics. Between April
997 and June 1998, a total of 1,205 patients were
andomly assigned to PCI with BMS (n  600) or
ABG (n  605) in 67 participating centers in the
RTS I trial. Between February 2003 and November
003, 607 patients at 45 participating centers were
reated by PCI using SES and entered into the ARTS II
tudy. Table 1 presents their baseline demographic and
ngiographic characteristics. Patients treated in ARTS II
ere significantly older than those in ARTS I. ARTS II
ad a significantly higher incidence of diabetes mellitus,
ypertension, hypercholesterolemia, and silent ischemia,
nd a lower percentage of current smokers or patients
ith a history of prior MI as compared with the CABG
roups. Seven patients did not receive any stents during
he index procedure (4 underwent elective CABG, 1
equired emergent CABG, 1 underwent PCI 35 days
ater, and 1 remained on medical therapy).
The percentage of percutaneous 3-vessel treatment was
6.6% in SES versus 18.0% in BMS (p  0.001). The mean
umber of significant lesions per patient was 3.6 1.3 in SES
ersus 2.8 1.0 in CABG (p 0.001) and 2.8 1.0 in BMS.
ES patients received 3.7  1.5 stents with an average total
tented length of 72 32 mm compared with 2.8 1.3 stents
nd 48  22 mm in BMS patients (p  0.001). In the SES
opulation, SYNTAX score and logistic euroSCORE were
0.8  9.51 and 2.16  15.2, respectively.
-year follow-up. MACCE. Clinical follow-up at 5 years
as available in 97.6% of ARTS II population (Fig. 1).
he 5-year event rates are depicted in Table 2 and Figure 2.
he survival rate in ARTS II was comparable to the historical,
urgical, and PCI groups from ARTS I (SES: 94.5%, CABG:
2.6%, BMS: 92.0%). The death/CVA/MI event-free survival
as 87.1% in ARTS II, versus 86.0% (log-rank p 0.42) and
he 81.9% (log-rank p  0.008) in the CABG and BMS
ohorts, respectively. At 5-years follow-up, the MACCE-free purvival rate in ARTS II (72.5%), which had been comparable
o the surgical cohort of ARTS I at 3 years, was significantly
ower than CABG (78.9%, p 0.02), and significantly higher
han BMS (58.5%, log-rank p  0.001).
T ACCORDING TO THE ARC DEFINITIONS. In ARTS II, a
otal of 57 patients (Table 3) experienced at least 1 stent
hrombotic event (definite, probable, or possible) at 5 years.
he rate of ST (definite or probable or possible) in ARTS II
as 1.5% at 30 days, 3.1% at 1 year, 4.4% at 2 years, 6.4% at
years, and 9.4% at 5 years, respectively. The rate of definite
T was 1.0% at 30 days, 1.6% at 1 year, 2.1% at 2 years, 3.5%
t 3 years, and 3.8% at 5 years. Among the 23 patients with
efinite ST, the numbers experiencing acute (30 days), late
30 days,1 year), and very late (1 year) ST were 6, 4, and
3, respectively. Four of the acute thrombotic events occurred
ithin the first 4 days post-procedure.
Although clopidogrel was only recommended for 3 months,
total of 266 patients were still using thienopyridines at 1 year.
he impact of ST on the ARC-defined patient-oriented
omposite end point is presented in Figure 3A. If none of these
T events (definite, probable, and possible) had occurred, the
vent-free rate from mortality, the composite of mortality or
ny MI, and the patient-oriented composite end point
ould have increased from 94.5%, 84.3%, 70.7% to 96.8%,
2.7%, 78.0%, respectively (absolute difference: 2.3%, 8.4%,
nd 7.3%).
MPACT OF SYNTAX SCORE ON CLINICAL OUTCOME. A sig-
ificant separation of MACCE-free survival was observed
hen patients were stratified according to SYNTAX score
ertiles, with low, intermediate, and high groups defined by
YNTAX scores of 16 (n  209), 16 to 24 (n  199)
Fig. 4). When compared with the lowest tertile group
SYNTAX score: 16, 5-year MACE-free rate: 80.1%),
oth the intermediate (SYNTAX score: 16 to 24) and high
SYNTAX score: 24) tertile groups demonstrated a lower
ACE-free survival rate (intermediate: 70.1%, log-rank
 0.02; high: 67.1%, p  0.001).
ultivariate analysis. Univariable and multivariable inde-
endent predictors for 5-year MACE and ST were presented
n Table 4. In univariate analysis, diabetes, logistic euro-
CORE, and SYNTAX score were significant predictors of
ACE. In multivariate analysis, diabetes (odds ratio [OR]:
.68 [95% CI: 1.24 to 2.28]), logistic euroSCORE (OR 1.09
95% CI: 1.003 to 1.14]), and SYNTAX score (OR: 1.68
95% CI: 1.24 to 2.28]) remained significant, although history
f carotid surgery was not. With respect to ST (definite,
robable, or possible), SYNTAX score, use of glycoprotein
Ib/IIIa inhibitors, and logistic euroSCORE were significant
redictors in the univariate analysis, whereas multivariate
nalysis demonstrated that only SYNTAX score (OR: 1.03
95% CI: 1.00 to 1.05]) and the use of glycoprotein IIb/IIIa
nhibitors (OR: 1.71 [95% CI: 0.99 to 1.32]) were independent
redictors of ST at 5 years.
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5-Year Outcomes of the ARTS II Trial March 16, 2010:1093–101iscussion
he current analysis reports the 5-year outcomes of patients
ith multivessel disease treated with SES, and historical
ohorts treated with CABG and BMS. The main findings
f the study are the following: 1) 5-year mortality was
imilar between SES, CABG, and BMS groups; 2) the
aseline and Procedural Characteristics of ARTS II and I PopulatioTable 1 Baseline and Procedural Characteristics of ARTS II and
SES
(n  607)
CABG
(n  605)
Baseline characteristics
Male sex 77 76
Age (yrs) 63 10 61 9
Body mass index (kg/m2) 27.5 4.1 27.4 3.7
Risk factors
Myocardial infarction 34 42
Diabetes 26 16
Hypertension 67 45
Hypercholesterolemia 74 58
Family history of MI or sudden
death at age 55 yrs
36 42
Current smoker 19 26
Peripheral vascular disease 7 5
Indication for treatment
Stable angina 53 58
Unstable angina 36 37
Silent ischemia 10 5
Angiographic characteristics
Ejection fraction 60 12 60 13
No. of lesions with stenosis 50% 3.6 1.3 2.8 1.0
No. of diseased vessels
1
2
3
0
46
54
4
66
30
Vessel territory with stenosis
(% of lesions)
Right coronary artery
Left main
Left anterior descending
Left circumflex artery
29
0
42
29
29
0
41
29
Lesion length (visual) (% of lesions)
Discreet (10 mm)
Tubular (10–20 mm)
Diffuse (20 mm)
61
27
12
68
25
7
Lesion classification (% of lesions)
Type A
Type B1
Type B2
Type C
7
23
56
14
7
31
54
8
Procedural characteristics
Bifurcation requiring double wiring 34 32
Number of stents implanted 3.7 1.5 —
Total stent length (mm) 72.5 32.1 —
Maximum dilatation pressure (atm) 16.4 2.9 —
Direct stenting (% of lesions) 34.6 —
Duration of procedure (min) 85 43 193 67
Post-procedural hospital stay (days) 3.4 2.7 9.6 4.9
alues are % or mean  SD. Data are expressed per patient unless stated otherwise.
BMS  bare-metal stent(s); CABG  coronary artery bypass graft; CI  confidence interval; MI-year composite safety end point of death, stroke, and MI wn the SES group was comparable to the CABG group, and
ower than the BMS group; 3) at 5 years, the MACCE rate
n the SES group was higher than the CABG group, which
as mainly driven by a higher rate of repeat revasculariza-
ion in the SES group; however, the MACCE rate of the
ES group remained lower than that of the BMS group;
) at 5-year follow-up, ST events (early, late, and very late)
pulation
MS
600)
SES/CABG
Difference (95% CI)
SES/BMS
Difference (95% CI)
7 0.6% (4.2% to 5.4%) 0.4% (5.2% to 4.4%)
 10 1.5 (0.4 to 2.6) 2.1 (1.0 to 3.2)
 3.7 0.2 (0.3 to 0.6) 0.3 (0.1 to 0.8)
4 7.6% (13.0% to2.1%) 9.9% (15.4% to4.4%)
9 10.3% (5.8% to 14.9%) 7.5% (2.8% to 12.2%)
5 22.3% (16.8% to 27.7%) 22.5% (17.1% to 28.0%)
8 16.4% (11.2% to 21.7%) 16.1% (10.8% to 21.4%)
9 6.0% (11.5% to0.5%) 3.2% (8.7% to 2.2%)
8 6.5% (11.2% to1.8%) 8.7% (13.4% to3.9%)
6 1.8% (0.9% to 4.5%) 1.4% (1.3% to 4.2%)
6 4.8% (10.4% to0.8%) 3.1% (8.7% to 2.5%)
8 0.8% (6.2% to 4.6%) 1.3% (6.7% to 4.2%)
6 5.6% (2.6% to 8.5%) 4.4% (1.3% to 7.5%)
 12 0.2 (1.6 to 1.3) 0.8 (2.2 to 0.7)
 1.0 0.8 (0.6 to 0.9) 0.8 (0.6 to 0.9)
4
9
7
3.4% (5.0% to1.8%)
20.1% (25.6% to14.6%)
23.5% (18.1% to 28.9%)
3.6% (5.3% to2.0%)
22.4% (27.9% to17.0%)
26.1% (20.7% to 31.4%)
1
0
9
9
0.4% (3.3% to 2.5%)
0.1% (0.2% to 0.1%)
0.4% (2.7% to 3.6%)
0.0% (2.9% to 3.0%)
2.1% (5.0% to 0.9%)
0.1% (0.2% to 0.1%)
2.1% (1.1% to 5.3%)
0.0% (2.9% to 3.0%)
6
7
7
7.3% (10.4% to4.2%)
2.0% (0.9% to 4.9%)
5.3% (3.4% to 7.2%)
4.7% (7.9% to1.5%)
0.1% (3.0% to 2.8%)
4.8% (2.9% to 6.7%)
6
6
0
8
0.0% (1.6% to 1.6%)
7.9% (10.8% to5.1%)
1.9% (1.3% to 5.1%)
6.0% (4.0% to 8.0%)
0.9% (0.7% to 2.5%)
3.0% (5.8% to0.2%)
3.7% (6.9% to0.5%)
5.9% (3.9% to 7.8%)
5 2.2% (0.9% to 5.3%) 0.6% (3.7% to 2.6%)
 1.3 — 0.9 (0.7 to 1.0)
 21.7 — 24.9 (21.8 to 28.1)
 2.8 — 1.7 (1.4 to 2.1)
3.3 — 31.3% (29.1% to 33.6%)
 50 108.2 (114.6 to101.8) 13.6 (18.9 to8.3)
 3.7 6.2 (6.6 to5.8) 0.5 (0.9 to0.2)
ardial infarction; PCI  percutaneous coronary intervention; SES  sirolimus-eluting stent(s).n I Po
B
(n 
7
61
27.2
4
1
4
5
3
2
5
3
61
2.8
6
2
3
3
2
6
2
2
6
3
2.8
47.6
14.6
99
3.9ere potentially involved in approximately one-third of
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March 16, 2010:1093–101 5-Year Outcomes of the ARTS II TrialACE events; and 5) baseline SYNTAX score has a role in
he prediction of 5-year MACCE events.
ong-term safety. Despite the more complex angio-
raphic profile and clinical risk factors in the SES cohort,
here was no difference in 5-year mortality between the
RTS II and I cohorts. Although the present study
ight have been underpowered to demonstrate any
ignificant difference in mortality, the findings concur
ith the meta-analyses of randomized trials of CABG
ersus BMS and more specifically, CABG versus mul-
Figure 1 Flow Chart of 5-Year Follow-Up
*Electrocardiogram (ECG) obtained by center. FUP  follow-up; GP  general prac
linical End Points at 5 Years (Hierarchical and NonhierarchicalACCE Up to 1,800 Days, Per Patient) Counted Si ce Date of ProTable 2 Clinical End Points at 5 Years (Hi rarchical and NonhieMACCE Up to 1,800 Days, Per Patient) Counted Since
SES
(n  607)
CABG
(n  602)*
Hierarchical
Death 33 (5.4) 43 (7.1)
CVA 17 (2.8) 16 (2.7)
MI 27 (4.4) 24 (4.0)
Death/CVA/MI 77 (12.7) 83 (13.8)
Revascularization 88 (14.5) 42 (7.0)
(re) CABG 15 (2.5) 5 (0.8)
(re) PTCA 73 (12) 37 (6.1)
Any MACCE 165 (27.2) 125 (20.8)
Nonhierarchical
CVA 22 (3.6) 20 (3.3)
MI 35 (5.8) 34 (5.6)
Revascularization 123 (20.3) 52 (8.6)
(re) CABG 17 (2.8) 7 (1.2)
(re) PTCA 108 (17.8) 49 (8.1)alues are n (%). *3 patients on the waiting list died.
CVA  cardiovascular accident; MACCE  major adverse cardiac and cerebrovascular event; PTCA  pivessel stenting with BMS (25,26). In the current study,
he composite end point of mortality, stroke, and MI was
owest in the SES group and was significantly better than
n the BMS cohort.
ong-term efficacy. The significantly higher MACCE
ate in the SES group compared with the CABG cohort
21.1% vs. 17.5%, p  0.02) at 5-years was not observed
onsistently through the study. At 1 year, the MACCE rate
as slightly lower in the SES cohort compared with the
ABG group, whereas at 2 and 3 years, following a
r.
rehical
of Procedure
BMS
(n  600)
SES/CABG
Difference (95% CI)
SES/BMS
Difference (95% CI)
47 (7.8) 1.7 (4.4 to 1.0) 2.4 (5.2 to 0.4)
19 (3.2)
41 (6.8)
07 (17.8) 1.1 (4.9 to 2.7) 5.1 (9.2 to1.1)
40 (23.3)
47 (7.8)
93 (15.5)
47 (41.2) 6.4 (1.6 to 11.2) 14 (19.3 to8.7)
23 (3.8) 0.3 (1.8 to 2.4) 0.2 (2.3 to 1.9)
49 (8.2) 0.1 (2.5 to 2.7) 2.4 (5.3 to 0.5)
81 (30.2) 11.6 (7.7 to 15.5) 9.9 (14.8 to5.0)
63 (10.5) 1.6 (0.1 to 3.2) 7.7 (10.5 to4.9)
38 (23.0) 9.7 (5.9 to 13.4) 5.2 (9.7 to0.7)titionecedurarc
Date
1
1
2
1
1ercutaneous transluminal coronary angioplasty; other abbreviations as in Table 1.
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5-Year Outcomes of the ARTS II Trial March 16, 2010:1093–101omparatively greater number of additional MACCE events
n the SES group, the overall MACCE rate was insignifi-
antly higher in the SES group compared with CABG
17,27). This reversal was mainly driven by the relatively
igher rates of reintervention in patients in SES compared
Figure 2 Kaplan-Meier Curves of Freedom From Clinical Events
Kaplan-Meier estimates up to 1,800 days of: (A) freedom from all-cause mortality; (B
tion (MI); (C) freedom from revascularization; and (D) freedom from major adverse ca
vention). ARTS  Arterial Revascularization Therapy Study; BMS  bare-metal stent(s)
T According to the ARC DefinitionsTable 3 ST According to the ARC Definitions
ARTS II
Death Up to
1,800 Days
MI Up to
1,800 Days*
Acute/subacute
(30 days)
9 (1.4%) 1/9 (11%) 9/9 (100%)
Late (1 yr) 9 (1.4%) 3/9 (30.0%) 4/9 (40.0%)
Very late (1 yr) 39 (6%) 10/39 (26%) 29/39 (74%)
Definite 23 (4%) 2/23 (9%) 19/23 (83%)
Definite or probable 46 (8%) 3/46 (7%) 42/46 (91%)
Definite, probable or
possible
57 (9%) 14/57 (25%) 42/57 (74%)o
MI according to ARC definition.
ARC  Academic research consortium; MImyocardial infarction; ST  stent thrombosis.ith CABG, such that the absolute difference in repeat
evascularization between the 2 groups increased progres-
ively from 4.2 % at 1 year to 6.2%, 7.9%, and 11.6% at 2,
, and 5 years, respectively. Therefore, the current trial
onfirms that surgical revascularization is more durable than
ercutaneous revascularization. It is noteworthy, however,
hat the freedom from surgical or percutaneous reinterven-
ion at 5 years increased from 69.1% in the BMS to 79.2%
n SES. Furthermore, at 5 years, only 2.8% of patients from
he SES cohort required CABG compared with 10.5% from
he BMS cohort.
T. Occurrence of late and very late ST has been
ecognized as a long-term safety concern with drug-
luting stents (28,29). Recent studies have suggested that
n patients with 2- and 3-vessel disease, ST negatively
mpacts long-term outcomes (30). There was a gradual
ise in the rate of ST during follow-up, but overall rates
om from a composite of death, cerebrovascular accident (CVA), or myocardial infarc-
nd cardiovascular events (MACCE) (all-cause mortality, any MI, CVA, or any reinter-
 coronary artery bypass graft; SES  sirolimus-eluting stent(s).) freed
rdiac a
; CABGf definite ST were similar to those reported in all-comer
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he impact of ST on safety outcomes, reassurance can be
btained by considering the rate of all-cause mortality
5-year mortality, SES: 5.4% vs. BMS: 7.8%) and MI
5-year MI, SES: 5.8% vs. BMS: 8.2%), because despite
he fact that two-thirds of the patients with definite ST
ustained an MI or underwent a repeat revascularization,
nly 2 of these 23 patients died at 5-year follow-up. The
T events from ARTS I PCI have not been reported
ecause of the absence of any adjudication of late and
ery late stent thrombotic events.
Figure 3 illustrates the fact that early, late, and very late,
s well as definite, probable, or possible ST all contributed
o a deterioration in the treatment effect expressed as
Possible stent thrombosis (any unexplained death)
Probable stent thrombosis (MI in the stented area)
DEATH/MI
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Figure 3 Kaplan-Meier Curves of Freedom
From ARC-Defined MACE, With or Without ST
Kaplan-Meier estimates of freedom from death (red lines), death or myocardial
infarction (MI) (orange lines), and major adverse cardiac events (MACE) (all-
cause mortality, MI, or revascularization) (yellow lines) according to Academic
Research Consortium (ARC) definition (A). Possible stent thrombosis (ST) is
superimposed on the Kaplan-Meier curves as a triangle, probable stent throm-
bosis as a square, and definite stent thrombosis as a circle. If all these ST-
related events had been eliminated (B), freedom from death at 5 years would
have increased from 94.5% to 96.8%, freedom from death or death/MI from
84.3% to 92.7%, and freedom from MACE from 70.5% to 78.0%. Please note
MI and MACE were readjudicated according to ARC definition. *All-cause death,
MI, or any revascularization according to ARC definition. Troponin was not col-
lected in the ARTS II.reedom from death, death/MI, and death/MI/repeat revas-ularization. Of the 176 patients who had a major adverse
ardiac event (ARC definitions), 22 had definite ST, 45
efinite or probable ST, and 56 definite, probable, or
ossible ST (32% of adverse events). Thus, one-third of
dverse events occurring during 5-year follow-up could be
xplained, and potentially prevented, by eliminating ST.
hese results emphasize the importance of optimal stent
mplantation, development of less thrombogenic devices
uch as DES with biocompatible or bioabsorbable coatings,
r fully bioabsorbable DES, and in addition, more effective
ntithrombotic therapies (31–35).
mpact of SYNTAX score on long-term clinical outcome.
he recently reported SYNTAX trial compared surgery
ith percutaneous treatment in patients with left main or
-vessel disease (36). Of interest, when patients with
-vessel disease from the SYNTAX trial were subdivided
nto tertiles of SYNTAX score (cutoff of 23 and 33), the
owest tertile group showed similar 1-year MACCE rates
100
- ARTS II SES SYNTAX Score Low <16 (n=209)
- ARTS II SES SYNTAX Score Intermediate >=16/ <24 (n=199)
- ARTS II SES SYNTAX Score High >=24 (n=199)
70.1%
80.1%
67.1%
Log-rank Low vs. Interm.  p=0.02
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Figure 4 Kaplan-Meier Curves of Freedom From
MACCE According to Tertiles of SYNTAX Score
Freedom from protocol-defined major adverse cardiac and cerebrovascular
event (MACCE) rate according to SYNTAX score tertiles (A). When the coronary
artery bypass graft (CABG) MACCE rate is superimposed, the lowest SYNTAX
score tertile shows a similar event rate at 5 years (B).
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5-Year Outcomes of the ARTS II Trial March 16, 2010:1093–101etween PCI and CABG. On the other hand, for the
ighest tertile groups, the 1-year MACCE rate was signif-
cantly higher in the PCI group (36).
After applying the tertile division of the SYNTAX score
o the ARTS II study (cutoffs 16 and 24), patients with a
core of 16 had a MACCE-free survival rate that was
reater than patients in the middle or highest tertiles. In
ddition, the SYNTAX score was identified as an indepen-
ent predictor of 5-year ST and MACE, indicating that it
as a role in the risk stratification of patients with multives-
el disease. Furthermore, the MACE rate was similar
etween the lowest tertiles of the ARTS II group and the
ntire surgical cohort from ARTS I (Fig. 4). These results
urther support the notion that patients with multivessel
isease and a low SYNTAX score may be adequately treated
ith PCI, whereas those patients with high SYNTAX
cores benefit more from CABG.
Of note, the cutoff values for the tertile division of the
YNTAX score in the SYNTAX trial (23 and 33) are for
bvious reasons different from those in the ARTS II trial
16 and 24). Further assessment of the distribution and
linical impact of the SYNTAX score in various populations
s warranted; however, only a propensity-matched analysis
ased on SYNTAX score will allow a definitive comparison
f outcomes between the SYNTAX randomized controlled
rial and the ARTS II registry.
tudy limitations. First, it was nonrandomized, and thus
he groups are not directly comparable, precluding a
ormal noninferiority comparison. In view of the higher
isks anticipated as a result of the greater severity of
isease in the ARTS II population compared with the
RTS I population, the clinical outcomes may be biased
gainst ARTS II; however, this may be partially offset by
ther advances in interventional technology. Statistical
djustment therefore might be required to correct for the
ifferences. This is currently being conducted and will be
resented in a separate report. Second, there was a 5-year
ime lag between the enrollment periods of the ARTS I
nd II cohorts. With recent improvements in surgical
echniques and concomitant medication (statins), it is
Independent Predictors of MACE and ST in theTable 4 Independent Predictors of MACE an
Variables
Univariable Predicto
Odds Ratio 95% C
MACE
Diabetes 1.82 1.35–2.
Logistic euroSCORE 1.11 1.03–1.
SYNTAX score 1.04 1.02–1.
Any ST
SYNTAX score 1.03 1.00–1.
Use of glycoprotein IIb/IIIa
inhibitor
1.68 0.99–2.
Logistic euroSCORE 1.14 0.99–1.
Major adverse cardiac events (MACE) are according to ARC definition
Abbreviations as in Tables 1 through 3.ore than likely that the clinical results of a true
1andomized trial would have come out more in favor of
urgical treatment. Third, the incidence and impact of
T was not readjudicated according to the ARC defini-
ions in the ARTS I study, which was primarily because
ieces of clinical information required for readjudication
ere missing and not obtainable retrospectively. Finally,
he baseline SYNTAX scores in the historical cohorts
ave not been calculated because the baseline cine-
ngiograms are no longer available.
eprint requests and correspondence: Dr. Patrick W. Serruys,
horaxcenter, Ba-583, ‘s Gravendijkwal 230, 3015 CE Rotterdam,
he Netherlands. E-mail: p.w.j.c.serruys@erasmusmc.nl.
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